E J Barkus1, J Stirling, R S Hopkins, S Lewis. 1. Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK. emma.j.barkus@manchester.ac.uk
Abstract
OBJECTIVE: Recent studies have suggested that cannabis use is a risk factor for developing schizophrenia. We tested the hypothesis that cannabis use increases the likelihood of psychosis-like experiences in non-clinical participants who scored highly on a measure of schizotypy. METHOD: The psychological effects of cannabis were assessed in 137 healthy individuals (76% female, mean age 22 years) using a newly developed questionnaire concerned with subjective experiences of the drug: the Cannabis Experiences Questionnaire. The questionnaire has three subscales: Pleasurable Experiences, Psychosis-Like Experiences and After-Effects. Respondents also completed the brief Schizotypal Personality Questionnaire. RESULTS: Cannabis use was reported by 72% of the sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable effects of cannabis use were not related to schizotypy score. CONCLUSION: High scoring schizotypes who use cannabis are more likely to experience psychosis-like phenomena at the time of use, and unpleasant after-effects. Our results are consistent with the hypothesis that cannabis use is a risk factor for full psychosis in this group. Copyright 2006 S. Karger AG, Basel.
OBJECTIVE: Recent studies have suggested that cannabis use is a risk factor for developing schizophrenia. We tested the hypothesis that cannabis use increases the likelihood of psychosis-like experiences in non-clinical participants who scored highly on a measure of schizotypy. METHOD: The psychological effects of cannabis were assessed in 137 healthy individuals (76% female, mean age 22 years) using a newly developed questionnaire concerned with subjective experiences of the drug: the Cannabis Experiences Questionnaire. The questionnaire has three subscales: Pleasurable Experiences, Psychosis-Like Experiences and After-Effects. Respondents also completed the brief Schizotypal Personality Questionnaire. RESULTS: Cannabis use was reported by 72% of the sample. Use per se was not significantly related to schizotypy. However, high scoring schizotypes were more likely to report both psychosis-like experiences and unpleasant after-effects associated with cannabis use. The pleasurable effects of cannabis use were not related to schizotypy score. CONCLUSION: High scoring schizotypes who use cannabis are more likely to experience psychosis-like phenomena at the time of use, and unpleasant after-effects. Our results are consistent with the hypothesis that cannabis use is a risk factor for full psychosis in this group. Copyright 2006 S. Karger AG, Basel.
Authors: Nicole D Andorko; Zachary B Millman; Elizabeth Klingaman; Deborah Medoff; Emily Kline; Jordan DeVylder; Gloria Reeves; Jason Schiffman Journal: Schizophr Res Date: 2018-03-09 Impact factor: 4.939
Authors: Paolo Taurisano; Giulio Pergola; Anna Monda; Linda A Antonucci; Pasquale Di Carlo; Francesco Piarulli; Roberta Passiatore; Marco Papalino; Raffaella Romano; Alfonso Monaco; Antonio Rampino; Aurora Bonvino; Annamaria Porcelli; Teresa Popolizio; Roberto Bellotti; Alessandro Bertolino; Giuseppe Blasi Journal: Brain Imaging Behav Date: 2021-02 Impact factor: 3.978
Authors: Luca Pauselli; Michael L Birnbaum; Beatriz Paulina Vázquez Jaime; Enrico Paolini; Mary E Kelley; Beth Broussard; Michael T Compton Journal: Schizophr Res Date: 2018-02-04 Impact factor: 4.939
Authors: Sinan Guloksuz; Lotta-Katrin Pries; Philippe Delespaul; Gunter Kenis; Jurjen J Luykx; Bochao D Lin; Alexander L Richards; Berna Akdede; Tolga Binbay; Vesile Altınyazar; Berna Yalınçetin; Güvem Gümüş-Akay; Burçin Cihan; Haldun Soygür; Halis Ulaş; EylemŞahin Cankurtaran; Semra Ulusoy Kaymak; Marina M Mihaljevic; Sanja Andric Petrovic; Tijana Mirjanic; Miguel Bernardo; Bibiana Cabrera; Julio Bobes; Pilar A Saiz; María Paz García-Portilla; Julio Sanjuan; Eduardo J Aguilar; José Luis Santos; Estela Jiménez-López; Manuel Arrojo; Angel Carracedo; Gonzalo López; Javier González-Peñas; Mara Parellada; Nadja P Maric; Cem Atbaşog Lu; Alp Ucok; Köksal Alptekin; Meram Can Saka; Celso Arango; Michael O'Donovan; Bart P F Rutten; Jim van Os Journal: World Psychiatry Date: 2019-06 Impact factor: 49.548
Authors: Marta Di Forti; Craig Morgan; Paola Dazzan; Carmine Pariante; Valeria Mondelli; Tiago Reis Marques; Rowena Handley; Sonija Luzi; Manuela Russo; Alessandra Paparelli; Alexander Butt; Simona A Stilo; Ben Wiffen; John Powell; Robin M Murray Journal: Br J Psychiatry Date: 2009-12 Impact factor: 9.319
Authors: Valeria Mondelli; Paola Dazzan; Nilay Hepgul; Marta Di Forti; Monica Aas; Alessandro D'Albenzio; Marco Di Nicola; Helen Fisher; Rowena Handley; Tiago Reis Marques; Craig Morgan; Serena Navari; Heather Taylor; Andrew Papadopoulos; Katherine J Aitchison; Robin M Murray; Carmine M Pariante Journal: Schizophr Res Date: 2009-09-13 Impact factor: 4.939
Authors: Michael L Birnbaum; Sean D Cleary; Claire Ramsay Wan; Luca Pauselli; Michael T Compton Journal: Early Interv Psychiatry Date: 2017-10-20 Impact factor: 2.732